NASDAQ:FATE Fate Therapeutics Q1 2025 Earnings Results & Report $1.98 -0.03 (-1.25%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more. Fate Therapeutics beat analyst expectations on both earnings and revenue in its Q1 2025 results, released May 13, 2025. The company reported EPS of -$0.32 versus the -$0.39 consensus estimate, while revenue of $1.63 million topped the $1.18 million estimate by $0.45 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 13, 2025TimeBefore Market OpensConference Call4:00 PM ET Fate Therapeutics EPS ResultsActual EPS-$0.32Consensus EPS -$0.39Beat/MissBeat by +$0.07One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersFate Therapeutics Revenue ResultsActual Revenue$1.63 millionExpected Revenue$1.18 millionBeat/MissBeat by +$445.00 thousandYoY Revenue GrowthN/AUpcoming EarningsFate Therapeutics' Q3 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Fate Therapeutics Q1 2025 Earnings FAQ Did Fate Therapeutics beat earnings estimates for Q1 2025? Fate Therapeutics (NASDAQ:FATE) reported earnings of -$0.32 per share for Q1 2025, beating the consensus estimate of -$0.39. The report was announced on Tuesday, May 13, 2025. What was Fate Therapeutics' revenue for Q1 2025? Fate Therapeutics reported revenue of $1.63 million for Q1 2025, against a consensus estimate of $1.18 million. When is Fate Therapeutics' next earnings date? Fate Therapeutics' next earnings date is estimated for Thursday, October 29, 2026. MarketBeat tracks confirmed and estimated earnings dates for Fate Therapeutics on the company's earnings history page. Fate Therapeutics Earnings HeadlinesFate Therapeutics Taps Jamie Harrell To Guide Commercial Strategy For FT819 And FT839October 12 at 9:35 AM | rttnews.comFate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell TherapiesOctober 12 at 9:35 AM | finance.yahoo.comWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock ahead of October 20. His system has spotted at least seven of the top 10 performers every year since 2016, including all ten in the 2022 bear market and every member of the Magnificent Seven before their run higher. Now Chaikin's Power Gauge is turning bullish on an under-the-radar company tied to next-generation AI data centers built under Executive Order 14363, technology he says uses 99 percent less electricity and space while offering far greater computing power.October 14 at 1:00 AM | Chaikin Analytics (Ad)Aprea Therapeutics (NASDAQ:APRE) versus Fate Therapeutics (NASDAQ:FATE) Head to Head ComparisonOctober 12 at 3:45 AM | americanbankingnews.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Rating of "Hold" from AnalystsOctober 9, 2026 | americanbankingnews.comAnalysts Conflicted on These Healthcare Names: Dexcom (DXCM) and Fate Therapeutics (FATE)October 6, 2026 | theglobeandmail.comSee More Fate Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fate Therapeutics and other key companies, straight to your email. Email Address About Fate TherapeuticsFate Therapeutics (NASDAQ:FATE) is a clinical-stage biopharmaceutical company focused on developing cellular immunotherapies for cancer and other serious diseases. The company uses its induced pluripotent stem cell (iPSC) platform to create standardized, “off-the-shelf” immune cells that can be manufactured in advance and administered to multiple patients. Its research and development programs include iPSC-derived natural killer (NK) cells and T cells, including genetically engineered cells designed to recognize and attack specific cancer targets. Fate Therapeutics has developed technologies intended to enhance the persistence, activity and scalability of these cell therapies, with programs historically directed toward hematologic malignancies and solid tumors. Founded in 2007 and headquartered in San Diego, California, Fate Therapeutics conducts research and clinical development primarily through its U.S. operations. The company’s products remain in development, and its pipeline and strategic priorities may change as clinical studies and regulatory discussions progress.View Fate Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
